Artesunate exerts specific cytotoxicity in retinoblastoma cells via CD71
- Authors:
- Fei Zhao
- Han Wang
- Patricilia Kunda
- Xuemei Chen
- Qiu-Ling Liu
- Tao Liu
-
Affiliations: Graduate Division, Xuzhou Medical College, Xuzhou, Jiangsu 221004, P.R. China, Poten Biomedical Institute for Cancer Immunotherapy, Shenzhen, Guangdong 518057, P.R. China, Department of Pediatrics, The General Hospital of The Chinese People's Armed Police Forces, Beijing 100039, P.R. China - Published online on: June 28, 2013 https://doi.org/10.3892/or.2013.2574
- Pages: 1473-1482
This article is mentioned in:
Abstract
 |
 |
 |
 |
|
Shields CL and Shields JA: Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus. 36:8–18; quiz 35–36. 1999. | |
|
Shields CL and Shields JA: Diagnosis and management of retinoblastoma. Cancer Control. 11:317–327. 2004. | |
|
Dimaras H, Kahaki K, O’Dimba EA, et al: Retinoblastoma. Lancet. 379:1436–1446. 2012. View Article : Google Scholar | |
|
Kivela T: The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death. Br J Ophthalmol. 93:1129–1131. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Bai S, Ren R, Shi J, et al: Retinoblastoma in the Beijing Tongren Hospital from 1957 to 2006: clinicopathological findings. Br J Ophthalmol. 95:1072–1076. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao J, Li S, Shi J and Wang N: Clinical presentation and group classification of newly diagnosed intraocular retinoblastoma in China. Br J Ophthalmol. 95:1372–1375. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Samaila MO: Malignant tumours of childhood in Zaria. Afr J Paediatr Surg. 6:19–23. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
MacCarthy A, Draper GJ, Steliarova-Foucher E and Kingston JE: Retinoblastoma incidence and survival in European children (1978–1997). Report from the Automated Childhood Cancer Information System project. Eur J Cancer. 42:2092–2102. 2006. | |
|
Broaddus E, Topham A and Singh AD: Incidence of retinoblastoma in the USA: 1975–2004. Br J Ophthalmol. 93:21–23. 2009. | |
|
Chantada G, Fandiño A, Manzitti J, Urrutia L and Schvartzman E: Late diagnosis of retinoblastoma in a developing country. Arch Dis Child. 80:171–174. 1999. View Article : Google Scholar : PubMed/NCBI | |
|
Schipper J, Tan KE and van Peperzeel HA: Treatment of retinoblastoma by precision megavoltage radiation therapy. Radiother Oncol. 3:117–132. 1985. View Article : Google Scholar : PubMed/NCBI | |
|
Gallie BL, Budning A, DeBoer G, et al: Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol. 114:1321–1328. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Kingston JE, Hungerford JL, Madreperla SA and Plowman PN: Results of combined chemotherapy and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol. 114:1339–1343. 1996. View Article : Google Scholar : PubMed/NCBI | |
|
Veal GJ and Boddy AV: Carboplatin dosing in infants with retinoblastoma: a case for therapeutic drug monitoring. J Clin Oncol. 30:34242012. View Article : Google Scholar : PubMed/NCBI | |
|
Rodriguez-Galindo C, Wilson MW, Haik BG, et al: Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol. 21:2019–2025. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Varan A, Kiratli H, Aydin B, et al: The treatment of retinoblastoma with four-drug regimen including cisplatin, etoposide, vincristine, and cyclophosphamide. Pediatr Hematol Oncol. 29:529–537. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chantada G, Fandino A, Casak S, Manzitti J, Raslawski E and Schvartzman E: Treatment of overt extraocular retinoblastoma. Med Pediatr Oncol. 40:158–161. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Gao YJ, Qian J, Yue H, Yuan YF, Xue K and Yao YQ: Clinical characteristics and treatment outcome of children with intraocular retinoblastoma: a report from a Chinese cooperative group. Pediatr Blood Cancer. 57:1113–1116. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Leahey A: A cautionary tale: dosing chemotherapy in infants with retinoblastoma. J Clin Oncol. 30:1023–1024. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Shields CL, Kaliki S, Shah SU, et al: Minimal exposure (one or two cycles) of intra-arterial chemotherapy in the management of retinoblastoma. Ophthalmology. 119:188–192. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Chan HS, Lu Y, Grogan TM, et al: Multidrug resistance protein (MRP) expression in retinoblastoma correlates with the rare failure of chemotherapy despite cyclosporine for reversal of P-glycoprotein. Cancer Res. 57:2325–2330. 1997.PubMed/NCBI | |
|
Gobin YP, Dunkel IJ, Marr BP, Brodie SE and Abramson DH: Intra-arterial chemotherapy for the management of retinoblastoma: four-year experience. Arch Ophthalmol. 129:732–737. 2011.PubMed/NCBI | |
|
Qaddoumi I, Bass JK, Wu J, et al: Carboplatin-associated ototoxicity in children with retinoblastoma. J Clin Oncol. 30:1034–1041. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Rizzuti AE, Dunkel IJ and Abramson DH: The adverse events of chemotherapy for retinoblastoma: What are they? Do we know? Arch Ophthalmol. 126:862–865. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Abramson DH, Lawrence SD, Beaverson KL, Lee TC, Rollins IS and Dunkel IJ: Systemic carboplatin for retinoblastoma: change in tumour size over time. Br J Ophthalmol. 89:1616–1619. 2005. View Article : Google Scholar : PubMed/NCBI | |
|
Marees T, van Leeuwen FE, de Boer MR, Imhof SM, Ringens PJ and Moll AC: Cancer mortality in long-term survivors of retinoblastoma. Eur J Cancer. 45:3245–3253. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Araki Y, Matsuyama Y, Kobayashi Y, et al: Secondary neoplasms after retinoblastoma treatment: retrospective cohort study of 754 patients in Japan. Jpn J Clin Oncol. 41:373–379. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Turaka K, Shields CL, Meadows AT and Leahey A: Second malignant neoplasms following chemoreduction with carboplatin, etoposide, and vincristine in 245 patients with intraocular retinoblastoma. Pediatr Blood Cancer. 59:121–125. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Tu Y: The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med. 17:1217–1220. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Balint G: Artemisinin and its derivatives: an important new class of antimalarial agents. Pharmacol Ther. 90:261–265. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
Chaturvedi D, Goswami A, Saikia PP, Barua NC and Rao PG: Artemisinin and its derivatives: a novel class of anti-malarial and anti-cancer agents. Chem Soc Rev. 39:435–454. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Efferth T, Giaisi M, Merling A, Krammer PH and Li-Weber M: artesunate induces ROS-mediated apoptosis in doxorubicin-resistant T leukemia cells. PLoS One. 2:e6932007. View Article : Google Scholar : PubMed/NCBI | |
|
Lai HC, Singh NP and Sasaki T: Development of artemisinin compounds for cancer treatment. Invest New Drugs. 31:230–246. 2013. View Article : Google Scholar : PubMed/NCBI | |
|
Gong Y, Gallis BM, Goodlett DR, et al: Effects of transferrin conjugates of artemisinin and artemisinin dimer on breast cancer cell lines. Anticancer Res. 33:123–132. 2013.PubMed/NCBI | |
|
Gong XM, Zhang Q, Torossian A, Cao JP and Fu S: Selective radiosensitization of human cervical cancer cells and normal cells by artemisinin through the abrogation of radiation-induced G2 block. Int J Gynecol Cancer. 22:718–724. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Kerb R, Fux R, Mörike K, Kremsner PG, Gil JP, Gleiter CH and Schwab M: Pharmacogenetics of antimalarial drugs: effect on metabolism and transport. Lancet Infect Dis. 9:760–774. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Efferth T, Benakis A, Romero MR, et al: Enhancement of cytotoxicity of artemisinins toward cancer cells by ferrous iron. Free Radic Biol Med. 37:998–1009. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Berdelle N, Nikolova T, Quiros S, Efferth T and Kaina B: artesunate induces oxidative DNA damage, sustained DNA double-strand breaks, and the ATM/ATR damage response in cancer cells. Mol Cancer Ther. 10:2224–2233. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Li YSF, Wu JM, Wu GS, Ding J, Xiao D, Yang WY, Atassi G, Léonce S, Caignard DH and Renard P: Novel antitumor artemisinin derivatives targeting G1 phase of the cell cycle. Bioorg Med Chem Lett. 11:5–8. 2001. View Article : Google Scholar : PubMed/NCBI | |
|
O’Neill PM, Barton VE and Ward SA: The molecular mechanism of action of artemisinin - the debate continues. Molecules. 15:1705–1721. 2010.PubMed/NCBI | |
|
Hentze MW, Muckenthaler MU, Galy B and Camaschella C: Two to tango: regulation of Mammalian iron metabolism. Cell. 142:24–38. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Shpyleva SI, Tryndyak VP, Kovalchuk O, et al: Role of ferritin alterations in human breast cancer cells. Breast Cancer Res Treat. 126:63–71. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Richardson DR, Kalinowski DS, Lau S, Jansson PJ and Lovejoy DB: Cancer cell iron metabolism and the development of potent iron chelators as anti-tumour agents. Biochim Biophys Acta. 1790:702–717. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Crespo-Ortiz MP and Wei MQ: Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug. J Biomed Biotechnol. 2012:2475972012.PubMed/NCBI | |
|
Altschul SF, Madden TL, Schäffer AA, Zhang J, Zhang Z, Miller W and Lipman DJ: Gapped BLAST and PSI-BLAST: a new generation of protein database search programs. Nucleic Acids Res. 25:3389–3402. 1997. View Article : Google Scholar : PubMed/NCBI | |
|
Green MD, Mount DL, Wirtz RA and White NJ: A colorimetric field method to assess the authenticity of drugs sold as the antimalarial artesunate. J Pharm Biomed Anal. 24:65–70. 2000. View Article : Google Scholar : PubMed/NCBI | |
|
Okwelogu C, Clark B, de Matas M, et al: Design of a fixed-dose paediatric combination of artesunate and amodiaquine hydrochloride. Int J Pharm. 387:19–25. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Calvert AH, Newell DR, Gumbrell LA, et al: Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 7:1748–1756. 1989.PubMed/NCBI | |
|
Shimokata T, Ando Y, Yasuda Y, et al: Prospective evaluation of pharmacokinetically guided dosing of carboplatin in Japanese patients with cancer. Cancer Sci. 101:2601–2605. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Krishnakumar S, Mallikarjuna K, Desai N, et al: Multidrug resistant proteins: P-glycoprotein and lung resistance protein expression in retinoblastoma. Br J Ophthalmol. 88:1521–1526. 2004. View Article : Google Scholar : PubMed/NCBI | |
|
Wilson MW, Fraga CH, Fuller CE, et al: Immunohistochemical detection of multidrug-resistant protein expression in retinoblastoma treated by primary enucleation. Invest Ophthalmol Vis Sci. 47:1269–1273. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Deng DA, Xu CH and Cai JC: Derivatives of arteannuin B with antileukemia activity. Yao Xue Xue Bao. 27:317–320. 1992.(In Chinese). | |
|
Sun WC, Han JX, Yang WY, Deng DA and Yue XF: Antitumor activities of 4 derivatives of artemisic acid and artemisinin B in vitro. Zhongguo Yao Li Xue Bao. 13:541–543. 1992.(In Chinese). | |
|
Woerdenbag HJ, Moskal TA, Pras N, et al: Cytotoxicity of artemisinin-related endoperoxides to Ehrlich ascites tumor cells. J Nat Prod. 56:849–856. 1993. View Article : Google Scholar : PubMed/NCBI | |
|
Yang XP, Pan QC, Ling YJ, et al: Study on antitumor effect of sodium artesunate. Cancer. 16:186–187. 1997.(In Chinese). | |
|
Efferth T, Dunstan H, Sauerbrey A, Miyachi H and Chitambar CR: The anti-malarial artesunate is also active against cancer. Int J Oncol. 18:767–773. 2001.PubMed/NCBI | |
|
Buommino E, Baroni A, Canozo N, et al: Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs. 27:412–418. 2009. View Article : Google Scholar : PubMed/NCBI | |
|
Morrissey C, Gallis B, Solazzi JW, et al: Effect of artemisinin derivatives on apoptosis and cell cycle in prostate cancer cells. Anticancer Drugs. 21:423–432. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Du JH, Zhang HD, Ma ZJ and Ji KM: Artesunate induces oncosis-like cell death in vitro and has antitumor activity against pancreatic cancer xenografts in vivo. Cancer Chemother Pharmacol. 65:895–902. 2010. View Article : Google Scholar : PubMed/NCBI | |
|
Efferth TSA, Olbrich A, Gebhart E, Rauch P, Weber HO, Hengstler JG, Halatsch ME, Volm M, Tew KD, Ross DD and Funk JO: Molecular modes of action of artesunate in tumor cell lines. Mol Pharmacol. 64:382–394. 2003. View Article : Google Scholar : PubMed/NCBI | |
|
Singh NP and Verma KB: Case report of a laryngeal squamous cell carcinoma treated with artesunate. Arch Oncol. 10:279–280. 2002. View Article : Google Scholar | |
|
Torti SV and Torti FM: Ironing out cancer. Cancer Res. 71:1511–1514. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Shterman N, Kupfer B and Moroz C: Comparison of transferrin receptors, iron content and isoferritin profile in normal and malignant human breast cell lines. Pathobiology. 59:19–25. 1991. View Article : Google Scholar : PubMed/NCBI | |
|
Daniels TR, Delgado T, Rodriguez JA, Helguera G and Penichet ML: The transferrin receptor part I: biology and targeting with cytotoxic antibodies for the treatment of cancer. Clin Immunol. 121:144–158. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Daniels TR, Delgado T, Helguera G and Penichet ML: The transferrin receptor part II: targeted delivery of therapeutic agents into cancer cells. Clin Immunol. 121:159–176. 2006. View Article : Google Scholar : PubMed/NCBI | |
|
Ba Q, Zhou N, Duan J, et al: Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1. PLoS One. 7:e427032012. View Article : Google Scholar : PubMed/NCBI | |
|
Eichhorn T, Schloissnig S, Hahn B, et al: Bioinformatic and experimental fishing for artemisinin-interacting proteins from human nasopharyngeal cancer cells. Mol Biosyst. 8:1311–1318. 2012. View Article : Google Scholar : PubMed/NCBI | |
|
Zhao Y, Jiang W, Li B, et al: Artesunate enhances radiosensitivity of human non-small cell lung cancer A549 cells via increasing NO production to induce cell cycle arrest at G2/M phase. Int Immunopharmacol. 11:2039–2046. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Mercer AE, Maggs JL, Sun XM, et al: Evidence for the involvement of carbon-centered radicals in the induction of apoptotic cell death by artemisinin compounds. J Biol Chem. 282:9372–9382. 2007. View Article : Google Scholar : PubMed/NCBI | |
|
Mercer AE, Copple IM, Maggs JL, O’Neill PM and Park BK: The role of heme and the mitochondrion in the chemical and molecular mechanisms of mammalian cell death induced by the artemisinin antimalarials. J Biol Chem. 286:987–996. 2011. View Article : Google Scholar : PubMed/NCBI | |
|
Lai H and Singh NP: Selective cancer cell cytotoxicity from exposure to dihydroartemisinin and holotransferrin. Cancer Lett. 91:41–46. 1995. View Article : Google Scholar : PubMed/NCBI | |
|
Lai H, Sasaki T and Singh NP: Targeted treatment of cancer with artemisinin and artemisinin-tagged iron-carrying compounds. Expert Opin Ther Targets. 9:995–1007. 2005. View Article : Google Scholar | |
|
Nakase I, Lai H, Singh NP and Sasaki T: Anticancer properties of artemisinin derivatives and their targeted delivery by transferrin conjugation. Int J Pharm. 354:28–33. 2008. View Article : Google Scholar : PubMed/NCBI | |
|
Kwok JC and Richardson DR: The iron metabolism of neoplastic cells: alterations that facilitate proliferation? Crit Rev Oncol Hematol. 42:65–78. 2002. View Article : Google Scholar : PubMed/NCBI | |
|
Hamacher-Brady A, Stein HA, Turschner S, et al: Artesunate activates mitochondrial apoptosis in breast cancer cells via iron-catalyzed lysosomal reactive oxygen species production. J Biol Chem. 286:6587–6601. 2011. View Article : Google Scholar | |
|
Krishna S, Bustamante L, Haynes RK and Staines HM: Artemisinins: their growing importance in medicine. Trends Pharmacol Sci. 29:520–527. 2008. View Article : Google Scholar | |
|
Kelter G, Steinbach D, Konkimalla VB, et al: Role of transferrin receptor and the ABC transporters ABCB6 and ABCB7 for resistance and differentiation of tumor cells towards artesunate. PLoS One. 2:e7982007. View Article : Google Scholar : PubMed/NCBI | |
|
Hartwig CL, Rosenthal AS, D’Angelo J, Griffin CE, Posner GH and Cooper RA: Accumulation of artemisinin trioxane derivatives within neutral lipids of Plasmodium falciparum malaria parasites is endoperoxide-dependent. Biochem Pharmacol. 77:322–336. 2009. View Article : Google Scholar : PubMed/NCBI |
